• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    F

    Fundación Con Vida

    53论文总数
    986引用总数

    论文量&引用量时间轴

    机构学者

    排序
    Nestor Llinas Quintero
    Nestor Llinas Quintero
    Clin Vida, Fdn Colombiana Cancerol
    论文:6引用:0H-index:0
    Javier Cuello-López
    Javier Cuello-López
    Fundación Con Vida
    论文:5引用:0H-index:0
    Abel Monteagudo Mendoza
    Abel Monteagudo Mendoza
    Herbario Vargas, Universidad Nacional de San Antonio Abad del Cusco
    论文:4引用:0H-index:0
    Mauricio Lema
    Mauricio Lema
    Clínica de Oncología Astorga
    论文:4引用:0H-index:0
    Laura López Agudelo
    Laura López Agudelo
    论文:4引用:0H-index:0
    Luzmila Arroyo
    Luzmila Arroyo
    Univ Autonoma Gabriel Rene Moreno
    论文:3引用:0H-index:0
    James Comiskey
    James Comiskey
    Inventory and Monitoring Program, National Park Service
    论文:3引用:0H-index:0
    Timothy J. Killeen
    Timothy J. Killeen
    Museo de Historia Natural “Noel Kempff Mercado”, Avenida Irala 565, Casilla 2489, Santa Cruz de la Sierra, Santa Cruz, Bolivia
    论文:3引用:0H-index:0
    Roel Brienen
    Roel Brienen
    School of Geography, Faculty of Environment, University of Leeds
    论文:3引用:0H-index:0

    论文(53)

    年份
    起
    –
    止
    排序
    1Do All Patients with Primary Retroperitoneal Sarcoma Benefit from Resection?
    Carol Jane Swallow, Sara Iadecola, Juliana Restrepo-Lopez, Deanna Ng,Francesco Barretta,Silva Ljevar, Costanza Figura, Wendy Johnston,Marco Fiore,Carlo Morosi, Elena DiBlasi,Roberta Sanfilippo,

    e23549 Background: We aimed to determine the impact of early recurrence on the prognosis of patients who have undergone resection of primary retroperitoneal sarcoma (RPS) and to discover which preoperative patient/tumor features predict early recurrence. Methods: Consecutive patients with primary non-metastatic RPS who were managed at two high volume RPS referral centers between 03/2012 and 10/2019 were identified from prospectively maintained institutional databases. The primary study endpoint was Overall Survival (OS), defined as the time from diagnosis to death from any cause, estimated by the KM method. Patients were grouped by Disease-Free Interval following resection (DFI = 0-6, 7-12, 13-18, 19-24, > 24 mos). Univariate and multivariable analyses (UVA, MVA) were performed. The Sarculator risk calculator and the Inflammatory Biomarkers Prognostic Index (IBPI) were assessed as potential predictors of early recurrence, defined as DFI 0-6 mos. Results: 651 patients (median age = 62.7yrs, IQR = 51.9-71.3; F:M = 301:350) met inclusion criteria and form the study cohort. Median follow-up time was 75.9 mos (IQR 58.6-99.5). 566 of the 651 (87%) patients underwent resection of their primary RPS, while 85 (13%) did not, most commonly due to suboptimal PS. Of the 566 patients who underwent resection, 259 (46%) had developed a recurrence by the time of last follow-up, while 307 patients (54%) had not recurred. In the 259 patients whose tumor recurred, 49 (19%) recurred within 6 mos of primary RPS resection, 42 (16%) between 7 and 12 mos, 35 (14%) between 13 and 18 mos, 31 (12%) between 19 and 24 mos, and 102 (39%) after 24 mos. Patients who developed recurrence within 6 mos of resection had similar OS from the time of diagnosis to the 85 patients who did not have a resection (1-year estimates: 77.3% [95% CI: 66.4-90.1] vs 65.7% [56.1-76.8], respectively; 2-year estimates: 51.6% [39.1-68.0] vs 42.7% [33.1-55.1], p = 0.32), while patients who relapsed more than 6 mos after resection had longer OS than either of these groups (p < 0.001). Upon MVA, the HR for death in patients who recurred within 6 mos vs. that of patients who were not resected was 0.96 (95% CI: 0.60-1.53). No standard clinico-pathologic variable available preoperatively could be identified that predicted recurrence within 6 mos of primary resection. Neither composite score (Sarculator, IBPI) was able to reliably predict recurrence within 6 mos. Conclusions: DFI from primary RPS resection to first recurrence was less than 6 mos in ≈20% of patients. DFI directly correlated with OS from time of diagnosis. Patients who recurred within 6 mos of resection had an equivalent OS to patients who didn’t undergo resection, raising the question of whether resection was of any benefit. Current efforts focus on discovery of genomic characteristics that reflect adverse biology/host response and are discoverable preoperatively, in order to improve patient selection for surgery and for neoadjuvant therapy.

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)
    引用
    AI阅读
    加入学术空间
    2Vibostolimab Coformulated with Pembrolizumab (vibo/pembro) for Previously Treated Advanced Mismatch Repair–deficient (dmmr) Endometrial Cancer: Results from Cohort B1 of the Phase 2 KEYVIBE-005 Study.
    Carlos Rojas,Ferry Eskens,Francois Ghiringhelli,Mustafa Ozguroglu,Christian Caglevic,Mahmut Gumus,Diego Tosi,Julien Grenier,Alejandro Falcon Gonzalez, Andres Arenas,Lucia Gonzalez-Cortijo,Andrew George Robinson,

    5502 Background: Treatment options for advanced endometrial cancer after failure of first-line chemotherapy are limited. In the KEYNOTE-158 study, pembro demonstrated durable antitumor activity (ORR, 48%; median DOR, not reached [NR]; median PFS, 13.1 mo; median OS, NR) and an acceptable safety profile in patients (pts) with previously treated advanced microsatellite instability-high/dMMR endometrial cancer. The immune checkpoints TIGIT and PD-L1 are upregulated in several tumor types, including endometrial cancer, and are heavily coexpressed in dMMR tumors, suggesting that dual TIGIT/PD-(L)1 blockade may be an effective therapeutic approach in advanced dMMR endometrial cancer. We present data from cohort B1 of the open-label phase 2 KEYVIBE-005 study (NCT05007106), which evaluated vibo/pembro (anti-TIGIT/anti–PD-1) in pts with previously treated advanced dMMR endometrial cancer. Methods: Eligible pts were aged ≥18 y with advanced dMMR endometrial cancer with progressive disease after 1 platinum-based chemotherapy regimen (or ≤2 lines if 1 was given in the [neo]adjuvant setting), no prior anti–PD-(L)1 therapy, and an ECOG PS of 0 or 1. Pts received vibo 200 mg coformulated with pembro 200 mg Q3W for ≤35 cycles (2 y). The primary end point was ORR per RECIST v1.1 by investigator assessment. Secondary end points included DOR and PFS per RECIST v1.1 by investigator assessment, OS, and safety. Results: A total of 40 pts were enrolled. Median age was 63 y and 60% of pts had ECOG PS 1; 31 pts had previously received 1 line of therapy in any setting and 9 pts had previously received ≥2 lines of therapy in any setting. The median time from first dose to data cutoff (Oct 24, 2023) was 17.2 mo (range, 7.7-23.4). At data cutoff, 23 pts had discontinued treatment and 17 were ongoing. The ORR was 65% (n = 26; 95% CI, 48-79); 5 pts (13%) had a complete response and 21 (53%) had a partial response. Median DOR was 13.7 mo (95% CI, 12.7-NR), and 75% of responders remained in response for ≥12 mo based on the Kaplan-Meier method for censored data. Median PFS was 15.0 mo (95% CI, 8.1-15.6) and the 12-mo PFS rate was 58%. Median OS was NR (95% CI, 16.1-NR) and the 12-mo OS rate was 82%. Treatment-related adverse events (AEs) occurred in 38 pts (95%). Grade 3 or 4 treatment-related AEs occurred in 14 pts (35%), of which the most common were arthritis (5%) and maculopapular rash (5%). Nine pts (23%) discontinued treatment due to a treatment-related AE. Any-grade immune-mediated AEs or infusion reactions occurred in 21 pts (53%) and grade 3 or 4 events occurred in 7 pts (18%). No deaths due to treatment-related AEs or immune-mediated AEs or infusion reactions occurred. Conclusions: Vibo/pembro demonstrated durable antitumor activity and a manageable safety profile in pts with previously treated advanced dMMR endometrial cancer. Clinical trial information: NCT05007106 .

    2024Journal of Clinical Oncology(2024)引用:1
    引用
    AI阅读
    加入学术空间
    3Sensitivity of South American Tropical Forests to an Extreme Climate Anomaly
    Amy C. Bennett,Thaiane Rodrigues de Sousa,Abel Monteagudo-Mendoza,Adriane Esquivel-Muelbert,Paulo S. Morandi,Fernanda Coelho de Souza,Wendeson Castro,Luisa Fernanda Duque,Gerardo Flores Llampazo,Rubens Manoel dos Santos,Eliana Ramos,Emilio Vilanova Torre,

    The tropical forest carbon sink is known to be drought sensitive, but it is unclear which forests are the most vulnerable to extreme events. Forests with hotter and drier baseline conditions may be protected by prior adaptation, or more vulnerable because they operate closer to physiological limits. Here we report that forests in drier South American climates experienced the greatest impacts of the 2015–2016 El Niño, indicating greater vulnerability to extreme temperatures and drought. The long-term, ground-measured tree-by-tree responses of 123 forest plots across tropical South America show that the biomass carbon sink ceased during the event with carbon balance becoming indistinguishable from zero (−0.02 ± 0.37 Mg C ha −1 per year). However, intact tropical South American forests overall were no more sensitive to the extreme 2015–2016 El Niño than to previous less intense events, remaining a key defence against climate change as long as they are protected.

    2023Nature Climate Change(2023)引用:63
    引用
    AI阅读
    加入学术空间
    4Author Correction: Native Diversity Buffers Against Severity of Non-Native Tree Invasions
    Camille S. Delavaux,Thomas W. Crowther,Constantin M. Zohner,Niamh M. Robmann,Thomas Lauber,Johan van den Hoogen,Sara Kuebbing,Jingjing Liang,Sergio de-Miguel,Gert-Jan Nabuurs,Peter B. Reich,Meinrad Abegg,
    2023Nature(2023)引用:3
    引用
    AI阅读
    加入学术空间
    5Uso De Naturalista Como Refuerzo Del Programa De Estudios De La Materia Ecología De Bachillerato
    Juan Luis Loredo Varela,Ana Arán Sánchez

    Naturalista es una plataforma para registrar e identificar la biodiversidad utilizando inteligencia artificial y la contribución de una comunidad que incluye expertos en distintas disciplinas del conocimiento y aficionados. En este estudio la aplicación Naturalista se utilizó para monitorear la biodiversidad local no doméstica de febrero a junio de 2021 con el objetivo de reforzar el programa de estudios de la materia Ecología en el Centro de Bachillerato Tecnológico agropecuario #147, en Meoqui, Chihuahua, y crear una cultura ambiental que detenga el actual deterioro ambiental del entorno local. El proceso de intervención consistió en el registro de la flora y fauna casera y local, no doméstica, por parte de los estudiantes, para su posterior identificación por la comunidad de Naturalista, la contestación de cuestionarios al inicio y término del proyecto y una bitácora electrónica, para determinar la percepción de conocimiento de la biodiversidad local y la problemática ambiental local. Además, se utilizó el diario docente para el registro y categorización de la información de la investigación. El método investigación-acción se utilizó para documentar el proyecto. En este proyecto se encontró que monitoreando la biodiversidad en un contexto educativo e investigativo se promueve la inclinación del estudiante por el contacto con la naturaleza, se fomenta la interacción interpersonal y emociones positivas y se permite apreciar la diversa problemática ambiental local, incidiendo en el desconocimiento del entorno local y la ingenuidad sobre la biodiversidad en adolescentes, relacionado a periodos largos frente a pantallas.

    2023Revista Latinoamericana Ogmios(2023)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 53 篇论文

    合作机构(100)

    Fundación Universitaria de Ciencias de la Salud合作论文 5
    Naturalis Biodiversity Center合作论文 4
    国家亚马逊研究所合作论文 4
    利兹大学合作论文 4
    埃克塞特大学合作论文 4
    Fundación Santa Fe de Bogotá合作论文 4
    Universidade Federal do Acre合作论文 4
    Hospital Universitario de Santander合作论文 4
    杜克大学合作论文 4
    牛津大学合作论文 4

    机构统计